: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Flying Publisher

COVID-19: Daily Top 10 Papers

Ovarian Neoplasms

Free Subscription

Articles published in Gynecol Oncol
Retrieve available abstracts of 403 articles:
HTML format

Single Articles

November 2021

RASMUSSEN M, Lim K, Rambech E, Andersen MH, et al
Corrigendum to "Lynch syndrome-associated epithelial ovarian cancer and its immunological profile" [Gynecologic Oncology 162 (2021) 686-693].
Gynecol Oncol. 2021 Nov 19. pii: S0090-8258(21)01601.
PubMed

MATUSZEWSKA K, Ten Kortenaar S, Pereira M, Santry LA, et al
Addition of an Fc-IgG induces receptor clustering and increases the in vitro efficacy and in vivo anti-tumor properties of the thrombospondin-1 type I repeats (3TSR) in a mouse model of advanced stage ovarian cancer.
Gynecol Oncol. 2021 Nov 16. pii: S0090-8258(21)01599.
PubMed Abstract available

MATTHEWS BJ, Qureshi MM, Fiascone SJ, Nitschmann CC, et al
Racial disparities in non-recommendation of adjuvant chemotherapy in stage II-III ovarian cancer.
Gynecol Oncol. 2021 Nov 13. pii: S0090-8258(21)01553.
PubMed Abstract available

WEEKS KS, Lynch CF, West M, Carnahan R, et al
Gynecologic oncologist impact on adjuvant chemotherapy care for stage II-IV ovarian cancer patients.
Gynecol Oncol. 2021 Nov 11. pii: S0090-8258(21)01555.
PubMed Abstract available

KHOJA L, Weber RP, Webb PM, Jordan SJ, et al
Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association.
Gynecol Oncol. 2021 Nov 11. pii: S0090-8258(21)01552.
PubMed Abstract available

MANNING-GEIST BL, Gordhandas SB, Giri DD, Iasonos A, et al
Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer.
Gynecol Oncol. 2021 Nov 8. pii: S0090-8258(21)01551.
PubMed Abstract available

October 2021

ROCCONI RP, Wilhite AM, Schambeau L, Scalici J, et al
A novel proteomic-based screening method for ovarian cancer using cervicovaginal fluids: A window into the abdomen.
Gynecol Oncol. 2021 Oct 29. pii: S0090-8258(21)01527.
PubMed Abstract available

CALO CA, Smith BQ, Dorayappan KDP, Saini U, et al
Aberrant expression of TMEM205 signaling promotes platinum resistance in ovarian cancer: An implication for the antitumor potential of DAP compound.
Gynecol Oncol. 2021 Oct 29. pii: S0090-8258(21)01520.
PubMed Abstract available

EKMANN-GADE AW, Hogdall CK, Seibaek L, Noer MC, et al
Incidence, treatment, and survival trends in older versus younger women with epithelial ovarian cancer from 2005 to 2018: A nationwide Danish study.
Gynecol Oncol. 2021 Oct 26. pii: S0090-8258(21)01525.
PubMed Abstract available

WALTER A, Rocconi RP, Monk BJ, Herzog TJ, et al
Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
Gynecol Oncol. 2021 Oct 23. pii: S0090-8258(21)01422.
PubMed Abstract available

TREDAN O, Provansal M, Abdeddaim C, Lardy-Cleaud A, et al
Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).
Gynecol Oncol. 2021 Oct 22. pii: S0090-8258(21)01402.
PubMed Abstract available

HARRISON R, Zighelboim I, Cloven NG, Marcus JZ, et al
Secondary cytoreductive surgery for recurrent ovarian cancer: An SGO clinical practice statement.
Gynecol Oncol. 2021 Oct 19. pii: S0090-8258(21)01452.
PubMed

MANYAM M, Stephens AJ, Kennard JA, LeBlanc J, et al
A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer.
Gynecol Oncol. 2021 Oct 19. pii: S0090-8258(21)01513.
PubMed Abstract available

GERNIER F, Gompel A, Rousset-Jablonski C, Kalbacher E, et al
Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study.
Gynecol Oncol. 2021 Oct 11. pii: S0090-8258(21)01419.
PubMed Abstract available

KONECNY GE, Hendrickson AEW, Davidson TM, Winterhoff BJ, et al
Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer.
Gynecol Oncol. 2021 Oct 9. pii: S0090-8258(21)01413.
PubMed Abstract available

LIU J, Burris H, Wang JS, Barroilhet L, et al
An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.
Gynecol Oncol. 2021 Oct 6. pii: S0090-8258(21)01403.
PubMed Abstract available

SHAH PD, Wethington SL, Pagan C, Latif N, et al
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
Gynecol Oncol. 2021 Oct 4. pii: S0090-8258(21)01322.
PubMed Abstract available

TEWARIE NMSB, van Driel WJ, van Ham M, Wouters MW, et al
Corrigendum to: Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA) [Gynecologic Oncology Volume 162, Issue 2, August 2021, Pages 331-338].
Gynecol Oncol. 2021 Oct 1. pii: S0090-8258(21)01392.
PubMed

CLAIR KH, Bristow RE
The urban-rural gap: Disparities in ovarian cancer survival among patients treated in tertiary centers.
Gynecol Oncol. 2021;163:3-4.
PubMed

September 2021

SWISHER EM, Kristeleit RS, Oza AM, Tinker AV, et al
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01329.
PubMed Abstract available

HA HI, Cho SH, Lim J, Lee YJ, et al
Incidence and treatment outcomes of ovarian sarcoma compared to epithelial ovarian cancer from the national cancer registry.
Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01383.
PubMed Abstract available

ATASEVEN B, Tripon D, Schwameis R, Harter P, et al
Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation - real life data.
Gynecol Oncol. 2021 Sep 23. pii: S0090-8258(21)01335.
PubMed Abstract available

HUANG T, Townsend MK, Dood RL, Sood AK, et al
Antihypertensive medication use and ovarian cancer survival.
Gynecol Oncol. 2021 Sep 20. pii: S0090-8258(21)01378.
PubMed Abstract available

WENZEL L, Huang HQ, Cella D, McKinney CO, et al
Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study.
Gynecol Oncol. 2021 Sep 18. pii: S0090-8258(21)01326.
PubMed Abstract available

GAILLARD S, Oaknin A, Ray-Coquard I, Vergote I, et al
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).
Gynecol Oncol. 2021 Sep 11. pii: S0090-8258(21)01330.
PubMed Abstract available

MOSS HA, Chen L, Hershman DL, Davidson B, et al
Adherence to PARP inhibitor therapy among women with ovarian cancer.
Gynecol Oncol. 2021 Sep 9. pii: S0090-8258(21)01323.
PubMed Abstract available

WERNER B, Yuwono N, Duggan J, Liu D, et al
Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer.
Gynecol Oncol. 2021;162:720-727.
PubMed Abstract available

CAMPBELL R, King MT, Ross TL, Cohen PA, et al
Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment.
Gynecol Oncol. 2021 Sep 1. pii: S0090-8258(21)01320.
PubMed Abstract available

August 2021

FUH KC, Bookman MA, Liu JF, Coleman RL, et al
Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer.
Gynecol Oncol. 2021 Aug 30. pii: S0090-8258(21)01318.
PubMed Abstract available

STEENBEEK MP, van Bommel MHD, Harmsen MG, Hoogerbrugge N, et al
Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy.
Gynecol Oncol. 2021 Aug 26. pii: S0090-8258(21)01317.
PubMed Abstract available

POZZAR RA, Xiong N, Hong F, Wright AA, et al
Perceived patient-centered communication, quality of life, and symptom burden in individuals with ovarian cancer.
Gynecol Oncol. 2021 Aug 25. pii: S0090-8258(21)00652.
PubMed Abstract available

LUTGENDORF SK, Ramirez E, Schrepf A, Valentine MC, et al
Rural residence is related to shorter survival in epithelial ovarian cancer patients.
Gynecol Oncol. 2021 Aug 13. pii: S0090-8258(21)00601.
PubMed Abstract available

WETHINGTON SL, Wahner-Hendrickson AE, Swisher EM, Kaufmann SH, et al
PARP inhibitor maintenance for primary ovarian cancer - A missed opportunity for precision medicine.
Gynecol Oncol. 2021 Aug 11. pii: S0090-8258(21)00647.
PubMed

WENTZENSEN N, O'Brien KM
Talc, body powder, and ovarian cancer: A summary of the epidemiologic evidence.
Gynecol Oncol. 2021 Aug 5. pii: S0090-8258(21)00598.
PubMed Abstract available

COLOMBO N, Moore K, Scambia G, Oaknin A, et al
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.
Gynecol Oncol. 2021 Aug 2. pii: S0090-8258(21)00578.
PubMed Abstract available

July 2021

BANTIE L, Tadesse S, Likisa J, Yu M, et al
Erratum to "A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer" [Gynecologic Oncology 159 (2020) 827-838].
Gynecol Oncol. 2021 Jul 30. pii: S0090-8258(21)00580.
PubMed

VILLANUEVA C, Chang J, Ziogas A, Bristow RE, et al
Ambient air pollution and ovarian cancer survival in California.
Gynecol Oncol. 2021 Jul 27. pii: S0090-8258(21)00602.
PubMed Abstract available

NANEZ A, Stram DA, Garcia C, Powell CB, et al
Ovarian cancer surveillance in the clinical follow up of women with known BRCA1 or BRCA2 pathogenic variants in a large health care system.
Gynecol Oncol. 2021 Jul 27. pii: S0090-8258(21)00600.
PubMed Abstract available

LAZURKO C, Clark M, Pulman K, Lennox G, et al
Hormone maintenance therapy for women with low-grade serous ovarian cancer in the front-line setting: A systematic review.
Gynecol Oncol. 2021 Jul 26. pii: S0090-8258(21)00589.
PubMed Abstract available

BASARAN D, Boerner T, Suhner J, Sassine D, et al
Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy.
Gynecol Oncol. 2021 Jul 23. pii: S0090-8258(21)00592.
PubMed Abstract available

EOH KJ, Park EY, Chang YJ, Ha HI, et al
The preventive effect of breastfeeding against ovarian cancer in BRCA1 and BRCA2 mutation carriers: A systematic review and meta-analysis.
Gynecol Oncol. 2021 Jul 22. pii: S0090-8258(21)00590.
PubMed Abstract available

MOSS HA, Perhanidis JA, Havrilesky LJ, Secord AA, et al
Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.
Gynecol Oncol. 2021 Jul 20. pii: S0090-8258(21)00588.
PubMed Abstract available

CIBULA D, Rob L, Mallmann P, Knapp P, et al
Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial.
Gynecol Oncol. 2021 Jul 19. pii: S0090-8258(21)00533.
PubMed Abstract available

ZENG H, Chen L, Zhang M, Luo Y, et al
Integration of histopathological images and multi-dimensional omics analyses predicts molecular features and prognosis in high-grade serous ovarian cancer.
Gynecol Oncol. 2021 Jul 15. pii: S0090-8258(21)00577.
PubMed Abstract available

RASMUSSEN M, Lim K, Rambech E, Andersen MH, et al
Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
Gynecol Oncol. 2021 Jul 15. pii: S0090-8258(21)00531.
PubMed Abstract available

KURODA Y, Chiyoda T, Kawaida M, Nakamura K, et al
ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer.
Gynecol Oncol. 2021 Jul 13. pii: S0090-8258(21)00536.
PubMed Abstract available

HERMENS M, van Altena AM, Bulten J, van Vliet HAAM, et al
Increased incidence of ovarian cancer in both endometriosis and adenomyosis.
Gynecol Oncol. 2021 Jul 12. pii: S0090-8258(21)00535.
PubMed Abstract available

HUFFMAN DL, Jayakrishnan TT, Shankar K, Peterson CE, et al
Disparities in ovarian cancer treatment and overall survival according to race: An update.
Gynecol Oncol. 2021 Jul 12. pii: S0090-8258(21)00541.
PubMed Abstract available

VAN DER PLOEG P, Uittenboogaard A, Thijs AMJ, Westgeest HM, et al
The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.
Gynecol Oncol. 2021 Jul 10. pii: S0090-8258(21)00538.
PubMed Abstract available

GRUNER M, Chambers LM, Yao M, Chichura A, et al
Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer.
Gynecol Oncol. 2021 Jul 8. pii: S0090-8258(21)00530.
PubMed Abstract available

KRASNER CN, Campos SM, Young CL, Chadda KR, et al
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer.
Gynecol Oncol. 2021 Jul 6. pii: S0090-8258(21)00532.
PubMed Abstract available

June 2021

BENOIT L DR, Zerbib J Dr, Koual M Dr, Nguyen-Xuan HT Dr, et al
What can we learn from the 10 mm lymph node size cut-off on the CT in advanced ovarian cancer at the time of interval debulking surgery?
Gynecol Oncol. 2021 Jun 30. pii: S0090-8258(21)00521.
PubMed Abstract available

SAFRA T, Waissengrin B, Gerber D, Bernstein-Molho R, et al
Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study.
Gynecol Oncol. 2021 Jun 22. pii: S0090-8258(21)00489.
PubMed Abstract available

BALDEWPERSAD TEWARIE NMS, van Driel WJ, van Ham M, Wouters MW, et al
Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA).
Gynecol Oncol. 2021 Jun 16. pii: S0090-8258(21)00436.
PubMed Abstract available

JIANG C, Li Z
Performance validation of the Mayo triage algorithm applied to individualize surgical management of advanced epithelial ovarian cancer.
Gynecol Oncol. 2021 Jun 16. pii: S0090-8258(21)00483.
PubMed Abstract available

VAN DER ZANDEN V, van Soolingen NJ, Viddeleer AR, Trum JW, et al
Low preoperative skeletal muscle density is predictive for negative postoperative outcomes in older women with ovarian cancer.
Gynecol Oncol. 2021 Jun 7. pii: S0090-8258(21)00445.
PubMed Abstract available

AGHAJANIAN C, Bookman MA, Fleming GF, Swisher EM, et al
Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.
Gynecol Oncol. 2021 Jun 7. pii: S0090-8258(21)00437.
PubMed Abstract available

CASPER AC, Parsons MW, Chipman J, Burt LM Jr, et al
Risk of secondary malignancies in ovarian cancer survivors: 52,680 patients analyzed with over 40 years of follow-up.
Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00440.
PubMed Abstract available

LI S, Bercow AS, Falzone M, Kalyanaraman R, et al
Risk of venous thromboembolism for ovarian cancer patients during first-line therapy after implementation of an Enhanced Recovery After Surgery (ERAS) protocol.
Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00438.
PubMed Abstract available

HANLEY GE, Kaur P, Berchuck A, Chase A, et al
Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada.
Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00427.
PubMed Abstract available

ALVAREZ SECORD A, O'Malley DM, Sood AK, Westin SN, et al
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Gynecol Oncol. 2021 Jun 2. pii: S0090-8258(21)00424.
PubMed Abstract available

SHARMA A, Singh M, Chauhan R, Malik PS, et al
Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial.
Gynecol Oncol. 2021 Jun 1. pii: S0090-8258(21)00431.
PubMed Abstract available

May 2021

FRANGOU E, Bertelli G, Love S, Mackean MJ, et al
OVPSYCH2: A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancer.
Gynecol Oncol. 2021 May 28. pii: S0090-8258(21)00430.
PubMed Abstract available

HAVRILESKY LJ, Scott AL, Davidson BA, Secord AA, et al
The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens.
Gynecol Oncol. 2021 May 27. pii: S0090-8258(21)00428.
PubMed Abstract available

DE JONG JM, Hoogendam JP, Braat AJAT, Zweemer RP, et al
The feasibility of folate receptor alpha- and HER2-targeted intraoperative fluorescence-guided cytoreductive surgery in women with epithelial ovarian cancer: A systematic review.
Gynecol Oncol. 2021 May 27. pii: S0090-8258(21)00423.
PubMed Abstract available

LIN J, Sharaf RN, Saganty R, Ahsan D, et al
Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis.
Gynecol Oncol. 2021 May 19. pii: S0090-8258(21)00407.
PubMed Abstract available

HEMMINGSEN CH, Kjaer SK, Bennetsen AKK, Dehlendorff C, et al
The association of reproductive factors with risk of non-epithelial ovarian cancer and comparison with serous ovarian cancer.
Gynecol Oncol. 2021 May 17. pii: S0090-8258(21)00404.
PubMed Abstract available

KIM SI, Yoon S, Kim TM, Cho JY, et al
Prognostic implications of body composition change during primary treatment in patients with ovarian cancer: A retrospective study using an artificial intelligence-based volumetric technique.
Gynecol Oncol. 2021 May 13. pii: S0090-8258(21)00363.
PubMed Abstract available

CHAM S, Huang Y, Melamed A, Worley MJ Jr, et al
Fragmentation of surgery and chemotherapy in the initial phase of ovarian cancer care and its association with overall survival.
Gynecol Oncol. 2021 May 5. pii: S0090-8258(21)00352.
PubMed Abstract available

GAMBLE CR, Huang Y, Wright JD, Hou JY, et al
Precision medicine testing in ovarian cancer: The growing inequity between patients with commercial vs medicaid insurance.
Gynecol Oncol. 2021 May 3. pii: S0090-8258(21)00345.
PubMed Abstract available

SIMS TT, Boruta DM
Sentinel lymph node isolated tumor cells in early staged endometrioid endometrial cancer: Utility or futility?
Gynecol Oncol. 2021;161:331-332.
PubMed

GILLEN J, Miller A, Bell-McGuinn KM, Schilder RJ, et al
Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
Gynecol Oncol. 2021;161:512-515.
PubMed Abstract available

April 2021

MULLINS MA, Ruterbusch JJ, Clarke P, Uppal S, et al
Continuity of care and receipt of aggressive end of life care among women dying of ovarian cancer.
Gynecol Oncol. 2021 Apr 27. pii: S0090-8258(21)00344.
PubMed Abstract available

GIANNONE G, Scotto G, Katsaros D, De Giorgi U, et al
Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature.
Gynecol Oncol. 2021 Apr 22. pii: S0090-8258(21)00328.
PubMed Abstract available

THUSGAARD CF, Korsholm M, Koldby KM, Kruse TA, et al
Epithelial ovarian cancer and the use of circulating tumor DNA: A systematic review.
Gynecol Oncol. 2021 Apr 20. pii: S0090-8258(21)00330.
PubMed Abstract available

SWAYZE EJ, Strzyzewski L, Avula P, Zebolsky AL, et al
The impact of expanding gynecologic oncology care to ovarian cancer patients in small cities and rural communities.
Gynecol Oncol. 2021 Apr 19. pii: S0090-8258(21)00331.
PubMed Abstract available

MARTINEZ A, Buckley M, Scalise CB, Katre AA, et al
Understanding the effect of mechanical forces on ovarian cancer progression.
Gynecol Oncol. 2021 Apr 19. pii: S0090-8258(21)00273.
PubMed Abstract available

ARTIOLI G, Giannone G, Valabrega G, Maggiorotto F, et al
Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21).
Gynecol Oncol. 2021 Apr 19. pii: S0090-8258(21)00324.
PubMed Abstract available

DENG M, Wu D, Zhang Y, Jin Z, et al
MiR-29c downregulates tumor-expressed B7-H3 to mediate the antitumor NK-cell functions in ovarian cancer.
Gynecol Oncol. 2021 Apr 17. pii: S0090-8258(21)00323.
PubMed Abstract available

NITECKI R, Fleming ND, Fellman BM, Meyer LA, et al
Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer.
Gynecol Oncol. 2021 Apr 15. pii: S0090-8258(21)00322.
PubMed Abstract available

GUPTA VG, Hirst J, Petersen S, Roby KF, et al
Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
Gynecol Oncol. 2021 Apr 15. pii: S0090-8258(21)00325.
PubMed Abstract available

TONE AA, McCuaig JM, Ricker N, Boghosian T, et al
The Prevent Ovarian Cancer Program (POCP): Identification of women at risk for ovarian cancer using complementary recruitment approaches.
Gynecol Oncol. 2021 Apr 13. pii: S0090-8258(21)00321.
PubMed Abstract available

FLEMING ND, Westin SN, Rauh-Hain JA, Soliman PT, et al
Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer.
Gynecol Oncol. 2021 Apr 7. pii: S0090-8258(21)00272.
PubMed Abstract available

CHASE DM, Neighbors J, Perhanidis J, Monk BJ, et al
Gastrointestinal symptoms and diagnosis preceding ovarian cancer diagnosis: Effects on treatment allocation and potential diagnostic delay.
Gynecol Oncol. 2021 Apr 1. pii: S0090-8258(21)00259.
PubMed Abstract available

CRAMER DW, Vitonis AF, Sasamoto N, Yamamoto H, et al
Epidemiologic and biologic correlates of serum HE4 and CA125 in women from the National Health and Nutritional Survey (NHANES).
Gynecol Oncol. 2021;161:282-290.
PubMed Abstract available

JOU J, Zimmer Z, Charo L, Yau C, et al
HIPEC after neoadjuvant chemotherapy and interval debulking is associated with development of platinum-refractory or -resistant disease.
Gynecol Oncol. 2021;161:25-33.
PubMed Abstract available

March 2021

MALLEN A, Todd S, Robertson SE, Kim J, et al
Impact of age, comorbidity, and treatment characteristics on survival in older women with advanced high grade epithelial ovarian cancer.
Gynecol Oncol. 2021 Mar 31. pii: S0090-8258(21)00228.
PubMed Abstract available

GIL-MORENO A, Alonso-Alconada L, Diaz-Feijoo B, Domingo S, et al
M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients.
Gynecol Oncol. 2021 Mar 29. pii: S0090-8258(21)00260.
PubMed Abstract available

CARTMEL B, Hughes M, Ercolano EA, Gottlieb L, et al
Randomized trial of exercise on depressive symptomatology and brain derived neurotrophic factor (BDNF) in ovarian cancer survivors: The Women's Activity and Lifestyle Study in Connecticut (WALC).
Gynecol Oncol. 2021 Mar 24. pii: S0090-8258(21)00195.
PubMed Abstract available

FILIPPOVA OT, Tin AL, Alonso J, Vickers AJ, et al
Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer.
Gynecol Oncol. 2021 Mar 24. pii: S0090-8258(21)00252.
PubMed Abstract available

LOREEN A, Polen-De C, Monk BJ, Jackson AL, et al
The role of blinded independent radiologic review in ovarian cancer clinical trials: Discerning the value.
Gynecol Oncol. 2021 Mar 12. pii: S0090-8258(21)00176.
PubMed

HASSELGREN E, Hertzberg D, Camderman T, Bjorne H, et al
Perioperative fluid balance and major postoperative complications in surgery for advanced epithelial ovarian cancer.
Gynecol Oncol. 2021 Mar 12. pii: S0090-8258(21)00179.
PubMed Abstract available

ROCCONI RP, Monk BJ, Walter A, Herzog TJ, et al
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
Gynecol Oncol. 2021 Mar 11. pii: S0090-8258(21)00229.
PubMed Abstract available

MORDEN CR, Farrell AC, Sliwowski M, Lichtensztejn Z, et al
Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples.
Gynecol Oncol. 2021 Mar 10. pii: S0090-8258(21)00199.
PubMed Abstract available

LAGO V, Montero B, Lopez S, Padilla-Iserte P, et al
Ultrastaging protocol in sentinel lymph node for apparent early stage ovarian cancer.
Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00193.
PubMed Abstract available

BUECHEL ME, Enserro D, Burger RA, Brady MF, et al
Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).
Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00177.
PubMed Abstract available

COWAN R, Nobre SP, Pradhan N, Yasukawa M, et al
Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers.
Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00142.
PubMed Abstract available

BACKES FJ, Felix AS, Plante M, Gregoire J, et al
Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?
Gynecol Oncol. 2021 Mar 4. pii: S0090-8258(21)00154.
PubMed Abstract available

HUANG C, Lin X, He J, Liu N, et al
Enrichment and detection method for the prognostic value of circulating tumor cells in ovarian cancer: A meta-analysis.
Gynecol Oncol. 2021 Mar 2. pii: S0090-8258(21)00169.
PubMed Abstract available

FILIPPOVA OT, Selenica P, Pareja F, Vahdatinia M, et al
Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
Gynecol Oncol. 2021 Mar 2. pii: S0090-8258(21)00173.
PubMed Abstract available

AUBREY C, Saad N, Kobel M, Mattatall F, et al
Implications for management of ovarian cancer in a transgender man: Impact of androgens and androgen receptor status.
Gynecol Oncol. 2021 Mar 1. pii: S0090-8258(21)00158.
PubMed Abstract available

February 2021

SCHRIER E, Xiong N, Thompson E, Poort H, et al
Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors.
Gynecol Oncol. 2021 Feb 23. pii: S0090-8258(21)00168.
PubMed Abstract available

SJOQUIST KM, Espinoza D, Mileshkin L, Ananda S, et al
REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.
Gynecol Oncol. 2021 Feb 23. pii: S0090-8258(21)00109.
PubMed Abstract available

AREND RC, Monk BJ, Herzog TJ, Moore KN, et al
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum r
Gynecol Oncol. 2021 Feb 23. pii: S0090-8258(21)00151.
PubMed Abstract available

DA CRUZ PAULA A, DeLair DF, Ferrando L, Fix DJ, et al
Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer.
Gynecol Oncol. 2021 Feb 20. pii: S0090-8258(21)00152.
PubMed Abstract available

KURTZ JE, Gebski V, Sukhin V, Carey M, et al
Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.
Gynecol Oncol. 2021 Feb 18. pii: S0090-8258(21)00155.
PubMed Abstract available

INCI MG, Anders L, Woopen H, Richter R, et al
Frailty Index for prediction of surgical outcome in ovarian cancer: Results of a prospective study.
Gynecol Oncol. 2021 Feb 16. pii: S0090-8258(21)00149.
PubMed Abstract available

BAANDRUP L, Dehlendorff C, Hertzum-Larsen R, Hannibal CG, et al
Prognostic impact of socioeconomic status on long-term survival of non-localized epithelial ovarian cancer The Extreme study.
Gynecol Oncol. 2021 Feb 11. pii: S0090-8258(21)00102.
PubMed Abstract available

HICKEY M, Moss KM, Brand A, Wrede CD, et al
What happens after menopause? (WHAM): A prospective controlled study of depression and anxiety up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
Gynecol Oncol. 2021 Feb 11. pii: S0090-8258(21)00108.
PubMed Abstract available

DAHM-KAHLER P, Holmberg E, Holtenman M, Radestad AF, et al
Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study.
Gynecol Oncol. 2021 Feb 10. pii: S0090-8258(21)00059.
PubMed Abstract available

CHAMBERS LM, Yao M, Morton M, Gruner M, et al
Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00099.
PubMed Abstract available

RAHIMY E, Usoz M, von Eyben R, Fujimoto D, et al
Phase II trial evaluating efficacy of a Fitbit program for improving the health of endometrial cancer survivors.
Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00093.
PubMed Abstract available

LIU S, Kasherman L, Fazelzad R, Wang L, et al
The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2021 Feb 2. pii: S0090-8258(21)00088.
PubMed Abstract available

January 2021

HARRISON RF, Cantor SB, Sun CC, Villanueva M, et al
Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer.
Gynecol Oncol. 2021 Jan 31. pii: S0090-8258(21)00084.
PubMed Abstract available

PIZZOFERRATO AC, Klein M, Fauvet R, Durand C, et al
Pelvic floor disorders and sexuality in women with ovarian cancer: A systematic review.
Gynecol Oncol. 2021 Jan 27. pii: S0090-8258(21)00086.
PubMed Abstract available

TOZZI R, Traill Z, Valenti G, Ferrari F, et al
A prospective study on the diagnostic pathway of patients with stage IIIC-IV ovarian cancer: Exploratory laparoscopy (EXL) + CT scan VS. CT scan.
Gynecol Oncol. 2021 Jan 26. pii: S0090-8258(21)00060.
PubMed Abstract available

KIM SR, Tone A, Kim RH, Cesari M, et al
Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study.
Gynecol Oncol. 2021 Jan 18. pii: S0090-8258(21)00002.
PubMed Abstract available

NOVIKOVA OV, Nosov VB, Panov VA, Novikova EG, et al
Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
Gynecol Oncol. 2021 Jan 15. pii: S0090-8258(21)00001.
PubMed Abstract available

CASTLE PE, Locke A, Tergas AI, Befano B, et al
The relationship of human papillomavirus and cytology co-testing results with endometrial and ovarian cancer diagnoses.
Gynecol Oncol. 2021 Jan 13. pii: S0090-8258(21)00052.
PubMed Abstract available

SCHEEPERS ERM, de Rooij BH, Pijnenborg JMA, van Huis-Tanja LH, et al
Perceived social support in patients with endometrial or ovarian cancer: A secondary analysis from the ROGY care study.
Gynecol Oncol. 2021 Jan 13. pii: S0090-8258(20)34246.
PubMed Abstract available

BILBAO M, Aikins JK, Ostrovsky O
Is routine omentectomy of grossly normal omentum helpful in surgery for ovarian cancer? A look at the tumor microenvironment and its clinical implications.
Gynecol Oncol. 2021 Jan 9. pii: S0090-8258(20)34248.
PubMed Abstract available

HAGEMANN IS, Deng W, Zaino RJ, Powell MA, et al
The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women.
Gynecol Oncol. 2021 Jan 7. pii: S0090-8258(20)34255.
PubMed Abstract available

DELLINGER TH, Han ES
State of the Science: The role of HIPEC in the treatment of ovarian cancer.
Gynecol Oncol. 2021 Jan 5. pii: S0090-8258(20)34243.
PubMed

HEUS C, Smorenburg A, Stoker J, Rutten MJ, et al
Visceral obesity and muscle mass determined by CT scan and surgical outcome in patients with advanced ovarian cancer. A retrospective cohort study.
Gynecol Oncol. 2021;160:187-192.
PubMed Abstract available

FADADU PP, Polen-De CL, McGree ME, Weaver AL, et al
Patients triaged to neoadjuvant chemotherapy have higher rates of sarcopenia: An opportunity for prehabilitation.
Gynecol Oncol. 2021;160:40-44.
PubMed Abstract available

December 2020

DUSKA LR, Krasner CN, O'Malley DM, Hays JL, et al
A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Gynecol Oncol. 2020 Dec 31. pii: S0090-8258(20)34228.
PubMed Abstract available

BOERNER T, Walch HS, Nguyen B, Iasonos A, et al
Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study.
Gynecol Oncol. 2020 Dec 29. pii: S0090-8258(20)34225.
PubMed Abstract available

LIANG MI, Chen L, Hershman DL, Hillyer GC, et al
Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients.
Gynecol Oncol. 2020 Dec 27. pii: S0090-8258(20)34218.
PubMed Abstract available

GHEZELAYAGH TS, Pennington KP, Norquist BM, Khasnavis N, et al
Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.
Gynecol Oncol. 2020 Dec 26. pii: S0090-8258(20)34178.
PubMed Abstract available

PHILP L, Tannenbaum S, Haber H, Saini A, et al
Effect of surgical approach on risk of recurrence after vaginal brachytherapy in early-stage high-intermediate risk endometrial cancer.
Gynecol Oncol. 2020 Dec 23. pii: S0090-8258(20)34174.
PubMed Abstract available

GUO Y, Jiang T, Ouyang L, Li X, et al
A novel diagnostic nomogram based on serological and ultrasound findings for preoperative prediction of malignancy in patients with ovarian masses.
Gynecol Oncol. 2020 Dec 20. pii: S0090-8258(20)34177.
PubMed Abstract available

BANVILLE AC, Wouters MCA, Oberg AL, Goergen KM, et al
Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer.
Gynecol Oncol. 2020 Dec 17. pii: S0090-8258(20)34176.
PubMed Abstract available

KARNEZIS AN, Chen SY, Chow C, Yang W, et al
Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines.
Gynecol Oncol. 2020 Dec 13. pii: S0090-8258(20)34175.
PubMed Abstract available

YUE H, Li W, Chen R, Wang J, et al
Stromal POSTN induced by TGF-beta1 facilitates the migration and invasion of ovarian cancer.
Gynecol Oncol. 2020 Dec 11. pii: S0090-8258(20)34154.
PubMed Abstract available

GOTOH O, Kiyotani K, Chiba T, Sugiyama Y, et al
Immunogenomic landscape of gynecologic carcinosarcoma.
Gynecol Oncol. 2020 Dec 6. pii: S0090-8258(20)34158.
PubMed Abstract available

STOVER EH, Fuh K, Konstantinopoulos PA, Matulonis UA, et al
Clinical assays for assessment of homologous recombination DNA repair deficiency.
Gynecol Oncol. 2020;159:887-898.
PubMed Abstract available

WANG Z, Yin P, Sun Y, Na L, et al
LGR4 maintains HGSOC cell epithelial phenotype and stem-like traits.
Gynecol Oncol. 2020;159:839-849.
PubMed Abstract available

FUH K, Mullen M, Blachut B, Stover E, et al
Homologous recombination deficiency real-time clinical assays, ready or not?
Gynecol Oncol. 2020;159:877-886.
PubMed Abstract available

VETTER MH, Castaneda A, Khan A, O'Malley DM, et al
A clinical classification system for grading platinum hypersensitivity reactions.
Gynecol Oncol. 2020;159:794-798.
PubMed Abstract available

November 2020

STRAUBHAR AM, Wolf JL, Zhou MQC, Iasonos A, et al
Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events.
Gynecol Oncol. 2020 Nov 30. pii: S0090-8258(20)34132.
PubMed Abstract available

HULSTAERT E, Morlion A, Levanon K, Vandesompele J, et al
Candidate RNA biomarkers in biofluids for early diagnosis of ovarian cancer: A systematic review.
Gynecol Oncol. 2020 Nov 27. pii: S0090-8258(20)34129.
PubMed Abstract available

WU L, Zhu J, Yin R, Wu X, et al
Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort.
Gynecol Oncol. 2020 Nov 26. pii: S0090-8258(20)34013.
PubMed Abstract available

CONSIDINE DPC, Jia G, Shu X, Schildkraut JM, et al
Genetically predicted circulating protein biomarkers and ovarian cancer risk.
Gynecol Oncol. 2020 Nov 24. pii: S0090-8258(20)34127.
PubMed Abstract available

CHO A, Lee SW, Park JY, Kim DY, et al
Continued medical treatment for persistent early endometrial cancer in young women.
Gynecol Oncol. 2020 Nov 24. pii: S0090-8258(20)34115.
PubMed Abstract available

CHELARIU-RAICU A, Nick A, Urban R, Gordinier M, et al
A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer.
Gynecol Oncol. 2020 Nov 23. pii: S0090-8258(20)34124.
PubMed Abstract available

KHATIB G, Seyfettinoglu S, Guzel AB, Gulec UK, et al
Feasibility and rationale of a novel approach in advanced ovarian cancer surgery: Bat- shaped en-bloc total peritonectomy and total hysterectomy salpingo-oophorectomy with or without rectosigmoid resection (Sarta-Bat approach).
Gynecol Oncol. 2020 Nov 21. pii: S0090-8258(20)34122.
PubMed Abstract available

FEJZO MS, Chen HW, Anderson L, McDermott MS, et al
Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
Gynecol Oncol. 2020 Nov 20. pii: S0090-8258(20)34116.
PubMed Abstract available

MORSE CB, Voillet V, Bates BM, Chiu EY, et al
Development of a clinically relevant ovarian cancer model incorporating surgical cytoreduction to evaluate treatment of micro-metastatic disease.
Gynecol Oncol. 2020 Nov 20. pii: S0090-8258(20)34117.
PubMed Abstract available

RANA HQ, Kipnis L, Hehir K, Cronin A, et al
Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer.
Gynecol Oncol. 2020 Nov 20. pii: S0090-8258(20)34111.
PubMed Abstract available

FREY MK, Chapman-Davis E, Glynn SM, Lin J, et al
Adapting and avoiding coping strategies for women with ovarian cancer during the COVID-19 pandemic.
Gynecol Oncol. 2020 Nov 19. pii: S0090-8258(20)34128.
PubMed Abstract available

XU Y, Jia Y, Zhang Q, Du Y, et al
Incidence and risk factors for postoperative venous thromboembolism in patients with ovarian cancer: Systematic review and meta-analysis.
Gynecol Oncol. 2020 Nov 18. pii: S0090-8258(20)34121.
PubMed Abstract available

WEEKS K, Lynch CF, West M, Carnahan R, et al
Rural disparities in surgical care from gynecologic oncologists among Midwestern ovarian cancer patients.
Gynecol Oncol. 2020 Nov 17. pii: S0090-8258(20)34114.
PubMed Abstract available

BOERNER T, Tanner E, Filippova O, Zhou QC, et al
Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Gynecol Oncol. 2020 Nov 16. pii: S0090-8258(20)34064.
PubMed Abstract available

O'TOOLE SA, Huang Y, Norris L, Power Foley M, et al
HE4 and CA125 as preoperative risk stratifiers for lymph node metastasis in endometrioid carcinoma of the endometrium: A retrospective study in a cohort with histological proof of lymph node status.
Gynecol Oncol. 2020 Nov 16. pii: S0090-8258(20)34112.
PubMed Abstract available

CHEN F, Bailey CE, Alvarez RD, Shu XO, et al
Adherence to treatment guidelines as a major determinant of survival disparities between black and white patients with ovarian cancer.
Gynecol Oncol. 2020 Nov 15. pii: S0090-8258(20)34062.
PubMed Abstract available

POORT H, Fenton ATHR, Thompson E, Dinardo MM, et al
Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study.
Gynecol Oncol. 2020 Nov 12. pii: S0090-8258(20)34056.
PubMed Abstract available

KIMBLE DC, Dvergsten E, Thomeas-McEwing V, Karovic S, et al
Evaluation of publicly available in vitro drug sensitivity models for ovarian and uterine cancer.
Gynecol Oncol. 2020 Nov 12. pii: S0090-8258(20)34066.
PubMed Abstract available

WALL JA, Meza-Perez S, Scalise CB, Katre A, et al
Manipulating the Wnt/beta-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
Gynecol Oncol. 2020 Nov 6. pii: S0090-8258(20)34053.
PubMed Abstract available

WESLEY E, Uppendahl LD, Felices M, Dahl C, et al
Cytomegalovirus and systemic inflammation at time of surgery is associated with worse outcomes in serous ovarian cancer.
Gynecol Oncol. 2020 Nov 6. pii: S0090-8258(20)34051.
PubMed Abstract available

BIZZARRI N, du Bois A, Fruscio R, De Felice F, et al
Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer?
Gynecol Oncol. 2020 Nov 6. pii: S0090-8258(20)34050.
PubMed Abstract available

BLANC-DURAND F, Genestie C, Galende EY, Gouy S, et al
Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape.
Gynecol Oncol. 2020 Nov 5. pii: S0090-8258(20)33955.
PubMed Abstract available

RUSSELL B, Hawarden A, Gee M, Edmondson RJ, et al
Propensity score matching confirms that primary surgery or neoadjuvant chemotherapy result in equivalent survival within a comprehensive cohort of patients with high-grade serous ovarian cancer.
Gynecol Oncol. 2020 Nov 4. pii: S0090-8258(20)34057.
PubMed Abstract available

DIAZ-FEIJOO B, Bebia V, Hernandez A, Gilabert-Estalles J, et al
Surgical complications comparing extraperitoneal vs transperitoneal laparoscopic aortic staging in early stage ovarian and endometrial cancer.
Gynecol Oncol. 2020 Nov 4. pii: S0090-8258(20)34060.
PubMed Abstract available

October 2020

RUBINSTEIN MM, Grisham RN, Cadoo K, Kyi C, et al
A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers.
Gynecol Oncol. 2020 Oct 30. pii: S0090-8258(20)34041.
PubMed Abstract available

ELAYAPILLAI S, Ramraj S, Benbrook DM, Bieniasz M, et al
Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer.
Gynecol Oncol. 2020 Oct 29. pii: S0090-8258(20)34018.
PubMed Abstract available

MATSUO K, Matsuzaki S, Nusbaum DJ, Maoz A, et al
Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer.
Gynecol Oncol. 2020 Oct 23. pii: S0090-8258(20)34049.
PubMed Abstract available

CEPPI L, Grassi T, Galli F, Buda A, et al
Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers.
Gynecol Oncol. 2020 Oct 16. pii: S0090-8258(20)34036.
PubMed Abstract available

HALL MR, Dehbi HM, Banerjee S, Lord R, et al
A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.
Gynecol Oncol. 2020 Oct 16. pii: S0090-8258(20)33958.
PubMed Abstract available

BARBER EL, Garg R, Persenaire C, Simon M, et al
Natural language processing with machine learning to predict outcomes after ovarian cancer surgery.
Gynecol Oncol. 2020 Oct 14. pii: S0090-8258(20)34012.
PubMed Abstract available

MORTON M, Chambers LM, Costales AB, Chichura A, et al
Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
Gynecol Oncol. 2020 Oct 13. pii: S0090-8258(20)33962.
PubMed Abstract available

MICHELS J, Genestie C, Dunant A, Caron O, et al
Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registry.
Gynecol Oncol. 2020 Oct 12. pii: S0090-8258(20)33960.
PubMed Abstract available

HAUNSCHILD CE, Tewari KS
The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.
Gynecol Oncol. 2020 Oct 11. pii: S0090-8258(20)33953.
PubMed Abstract available

CARR C, Son J, Yao M, Priyadarshini A, et al
Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening.
Gynecol Oncol. 2020 Oct 9. pii: S0090-8258(20)33949.
PubMed Abstract available

NICA A, Lee JYJ, Hong NL, May T, et al
Cost-effectiveness of maintenance hormonal therapy in patients with advanced low grade serous ovarian cancer.
Gynecol Oncol. 2020 Oct 6. pii: S0090-8258(20)33961.
PubMed Abstract available

CORVIGNO S, Mezheyeuski A, De La Fuente LM, Westbom-Fremer S, et al
High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer.
Gynecol Oncol. 2020 Oct 5. pii: S0090-8258(20)33951.
PubMed Abstract available

CICCONE MA, Adams CL, Bowen C, Thakur T, et al
Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells.
Gynecol Oncol. 2020 Oct 5. pii: S0090-8258(20)33950.
PubMed Abstract available

UBACHS J, Koole SN, Lahaye M, Fabris C, et al
No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study.
Gynecol Oncol. 2020 Oct 2. pii: S0090-8258(20)33952.
PubMed Abstract available

GERSHENSON DM, Cobb LP, Sun CC
Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for the relative efficacy of tamoxifen and aromatase inhibitors.
Gynecol Oncol. 2020 Oct 2. pii: S0090-8258(20)33959.
PubMed

LENTZ SE, Powell CB, Haque R, Armstrong MA, et al
Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations.
Gynecol Oncol. 2020 Oct 1. pii: S0090-8258(20)33914.
PubMed Abstract available

EAKIN CM, Ewongwo A, Pendleton L, Monk BJ, et al
Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice.
Gynecol Oncol. 2020;159:112-117.
PubMed Abstract available

SALANI R, Liu JF
Meeting report from the 2020 Annual (virtual) Meeting of the American Society of Clinical Oncology.
Gynecol Oncol. 2020;159:13-16.
PubMed

CRESTANI A, Benoit L, Touboul C, Pasquier J, et al
Hyperthermic intraperitoneal chemotherapy (HIPEC): Should we look closer at the microenvironment?
Gynecol Oncol. 2020;159:285-294.
PubMed Abstract available

September 2020

KOTSOPOULOS J, Gronwald J, McCuaig JM, Karlan BY, et al
Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation.
Gynecol Oncol. 2020 Sep 30. pii: S0090-8258(20)33947.
PubMed Abstract available

CHAN JK, Liang SY, Kapp DS, Chan JE, et al
Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance.
Gynecol Oncol. 2020 Sep 26. pii: S0090-8258(20)33910.
PubMed

LANDOLFO C, Achten ETL, Ceusters J, Baert T, et al
Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors.
Gynecol Oncol. 2020 Sep 26. pii: S0090-8258(20)33918.
PubMed Abstract available

MIRZA MR, Benigno B, Dorum A, Mahner S, et al
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
Gynecol Oncol. 2020 Sep 24. pii: S0090-8258(20)33899.
PubMed Abstract available

WICHMANN C, Klotz DM, Zeiler HJ, Hilger RA, et al
The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.
Gynecol Oncol. 2020 Sep 23. pii: S0090-8258(20)33911.
PubMed Abstract available

MANRRIQUEZ E, Mandelbaum A, Aguayo E, Zakhour M, et al
Factors associated with high-cost hospitalizations in elderly ovarian cancer patients.
Gynecol Oncol. 2020 Sep 23. pii: S0090-8258(20)33919.
PubMed Abstract available

CHARO LM, Jou J, Binder P, Hohmann SF, et al
Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States.
Gynecol Oncol. 2020 Sep 22. pii: S0090-8258(20)33915.
PubMed Abstract available

JOHNSON KE, Popratiloff A, Fan Y, McDonald S, et al
Analytic comparison of talc in commercially available baby powder and in pelvic tissues resected from ovarian carcinoma patients.
Gynecol Oncol. 2020 Sep 22. pii: S0090-8258(20)33921.
PubMed Abstract available

EAKIN CM, Norton TJ, Monk BJ, Chase DM, et al
Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer.
Gynecol Oncol. 2020 Sep 21. pii: S0090-8258(20)33817.
PubMed Abstract available

MUSORO JZ, Coens C, Greimel E, King MT, et al
Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.
Gynecol Oncol. 2020 Sep 21. pii: S0090-8258(20)33900.
PubMed Abstract available

BANTIE L, Tadesse S, Likisa J, Yu M, et al
A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer.
Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33905.
PubMed Abstract available

GUNAY G, Kirit HA, Kamatar A, Baghdasaryan O, et al
The effects of size and shape of the ovarian cancer spheroids on the drug resistance and migration.
Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33857.
PubMed Abstract available

MUSTON D, Hettle R, Monberg M, McLaurin KK, et al
Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.
Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33814.
PubMed Abstract available

KANBERGS AN, Manning-Geist BL, Pelletier A, Sullivan MW, et al
Neoadjuvant chemotherapy does not disproportionately influence post-operative complication rates or time to chemotherapy in obese patients with advanced-stage ovarian cancer.
Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33904.
PubMed Abstract available

JORDAN SE, Saad H, Covarrubias AS, Siemon J, et al
mRNA expression in low grade serous ovarian cancer: Results of a nanoString assay in a diverse population.
Gynecol Oncol. 2020 Sep 17. pii: S0090-8258(20)33831.
PubMed Abstract available

CHAMBERS LM, Kuznicki M, Yao M, Chichura A, et al
Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer.
Gynecol Oncol. 2020 Sep 16. pii: S0090-8258(20)33903.
PubMed Abstract available

PALMQVIST C, Staf C, Mateoiu C, Johansson M, et al
Increased disease-free and relative survival in advanced ovarian cancer after centralized primary treatment.
Gynecol Oncol. 2020 Sep 15. pii: S0090-8258(20)33897.
PubMed Abstract available

HURWITZ LM, Pinsky PF, Huang WY, Freedman ND, et al
Aspirin use and ovarian cancer risk using extended follow-up of the PLCO Cancer Screening Trial.
Gynecol Oncol. 2020 Sep 10. pii: S0090-8258(20)33855.
PubMed Abstract available

PLETT H, Filippova OT, Garbi A, Kommoss S, et al
Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study.
Gynecol Oncol. 2020 Sep 9. pii: S0090-8258(20)33829.
PubMed Abstract available

MADARIAGA A, Garg S, Bruce JP, Thiryayi S, et al
Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer.
Gynecol Oncol. 2020 Sep 7. pii: S0090-8258(20)33849.
PubMed Abstract available

WALLBILLICH JJ, Morris RT, Ali-Fehmi R
Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma.
Gynecol Oncol. 2020 Sep 5. pii: S0090-8258(20)33813.
PubMed Abstract available

DI DONATO V, Di Pinto A, Giannini A, Caruso G, et al
Modified fragility index and surgical complexity score are able to predict postoperative morbidity and mortality after cytoreductive surgery for advanced ovarian cancer.
Gynecol Oncol. 2020 Sep 4. pii: S0090-8258(20)33823.
PubMed Abstract available

August 2020

SIA TY, Wen T, Cham S, Friedman AM, et al
Effect of frailty on postoperative readmissions and cost of care for ovarian cancer.
Gynecol Oncol. 2020 Aug 28. pii: S0090-8258(20)33825.
PubMed Abstract available

GONZALEZ R, Havrilesky LJ, Myers ER, Secord AA, et al
Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer.
Gynecol Oncol. 2020 Aug 27. pii: S0090-8258(20)33759.
PubMed Abstract available

SHEN L, Xie L, Li R, Shan B, et al
A preoperative prediction model for predicting coexisting adnexa malignancy of patients with G1/G2 endometrioid endometrial cancer.
Gynecol Oncol. 2020 Aug 23. pii: S0090-8258(20)33818.
PubMed Abstract available

BELL SG, Dalton L, McNeish BL, Fang F, et al
Aromatase inhibitor use, side effects and discontinuation rates in gynecologic oncology patients.
Gynecol Oncol. 2020 Aug 23. pii: S0090-8258(20)33816.
PubMed Abstract available

RICHARDSON MT, Mysona DP, Klein DA, Mann A, et al
Long term survival outcomes of stage I mucinous ovarian cancer - A clinical calculator predictive of chemotherapy benefit.
Gynecol Oncol. 2020 Aug 20. pii: S0090-8258(20)32386.
PubMed Abstract available

AVIKI EM, Lavery JA, Roche KL, Cowan R, et al
Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer.
Gynecol Oncol. 2020 Aug 16. pii: S0090-8258(20)33754.
PubMed Abstract available

BOERNER T, Filippova OT, Chi AJ, Iasonos A, et al
Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study.
Gynecol Oncol. 2020 Aug 10. pii: S0090-8258(20)33751.
PubMed Abstract available

POTHURI B, O'Cearbhaill R, Eskander R, Armstrong D, et al
Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement.
Gynecol Oncol. 2020 Aug 7. pii: S0090-8258(20)33747.
PubMed Abstract available

POWELL CB, Laurent C, Ciaravino G, Garcia C, et al
Streamlining genetic testing for women with ovarian cancer in a Northern California health care system.
Gynecol Oncol. 2020 Aug 7. pii: S0090-8258(20)33662.
PubMed Abstract available

BEESLEY VL, Webber K, Nagle CM, DeFazio A, et al
When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer.
Gynecol Oncol. 2020 Aug 6. pii: S0090-8258(20)33664.
PubMed Abstract available

LEE EK, Xiong N, Cheng SC, Barry WT, et al
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
Gynecol Oncol. 2020 Aug 5. pii: S0090-8258(20)33663.
PubMed Abstract available

July 2020

LEE JM, Annunziata CM, Hays JL, Cao L, et al
Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment.
Gynecol Oncol. 2020 Jul 31. pii: S0090-8258(20)33677.
PubMed Abstract available

COLOMBO N, Oza AM, Lorusso D, Aghajanian C, et al
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.
Gynecol Oncol. 2020 Jul 31. pii: S0090-8258(20)31130.
PubMed Abstract available

TEWARI KS, Sill MW, Coleman RL, Aghajanian C, et al
Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study.
Gynecol Oncol. 2020 Jul 25. pii: S0090-8258(20)32390.
PubMed Abstract available

SCHWARTZ GG, Tretli S, Klug MG, Robsahm TE, et al
Women who develop ovarian cancer show an increase in serum calcium and a decrease in serum albumin. A longitudinal study in the Janus Serum Bank Cohort.
Gynecol Oncol. 2020 Jul 25. pii: S0090-8258(20)32381.
PubMed Abstract available

BLANC-DURAND F, Lefeuvre-Plesse C, Ray-Coquard I, Chaltiel D, et al
Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT).
Gynecol Oncol. 2020 Jul 25. pii: S0090-8258(20)33654.
PubMed Abstract available

ROBELIN P, Tod M, Colomban O, Lachuer J, et al
Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study).
Gynecol Oncol. 2020 Jul 22. pii: S0090-8258(20)33656.
PubMed Abstract available

FALCONER H, Joneborg U, Krawiec K, Palsdottir K, et al
Ultra-radical upfront surgery does not improve survival in women with advanced epithelial ovarian cancer; a natural experiment in a complete population.
Gynecol Oncol. 2020 Jul 22. pii: S0090-8258(20)32384.
PubMed Abstract available

ANGELES MA, Rychlik A, Cabarrou B, Spagnolo E, et al
A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.
Gynecol Oncol. 2020 Jul 22. pii: S0090-8258(20)32321.
PubMed Abstract available

COBB LP, Sun CC, Iyer R, Nick AM, et al
The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance.
Gynecol Oncol. 2020 Jul 22. pii: S0090-8258(20)32324.
PubMed Abstract available

WEISS AS, Swisher E, Pennington KP, Radke M, et al
Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years.
Gynecol Oncol. 2020 Jul 21. pii: S0090-8258(20)32335.
PubMed Abstract available

LORUSSO D, Marchetti C, Conte C, Giudice E, et al
Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study.
Gynecol Oncol. 2020 Jul 20. pii: S0090-8258(20)33657.
PubMed Abstract available

TAYLAN E, Zayou F, Murali R, Karlan BY, et al
Dual targeting of GSK3B and HDACs reduces tumor growth and improves survival in an ovarian cancer mouse model.
Gynecol Oncol. 2020 Jul 19. pii: S0090-8258(20)32380.
PubMed Abstract available

WU JL, Zhao J, Zhang HB, Zuo WW, et al
Genetic variants and expression of the TIM-3 gene are associated with clinical prognosis in patients with epithelial ovarian cancer.
Gynecol Oncol. 2020 Jul 18. pii: S0090-8258(20)32387.
PubMed Abstract available

ZHENG L, Cui C, Shi O, Lu X, et al
Incidence and mortality of ovarian cancer at the global, regional, and national levels, 1990-2017.
Gynecol Oncol. 2020 Jul 18. pii: S0090-8258(20)32383.
PubMed Abstract available

MCCUAIG JM, Care M, Ferguson SE, Kim RH, et al
Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system.
Gynecol Oncol. 2020 Jul 13. pii: S0090-8258(20)32333.
PubMed Abstract available

ROSS TL, DeFazio A, Friedlander M, Grant P, et al
Insomnia and its association with quality of life in women with ovarian cancer.
Gynecol Oncol. 2020 Jul 9. pii: S0090-8258(20)32326.
PubMed Abstract available

PRESSEY JG, Dandoy CE, Pater LE, Sroga Rios J, et al
Small cell carcinoma of the ovary hypercalcemic type (SCCOHT): Comprehensive management of a newly diagnosed young adult.
Gynecol Oncol. 2020 Jul 9. pii: S0090-8258(20)31975.
PubMed Abstract available

BERNARD L, Boucher J, Helpman L
Bowel resection or repair at the time of cytoreductive surgery for ovarian malignancy is associated with increased complication rate: An ACS-NSQIP study.
Gynecol Oncol. 2020 Jul 6. pii: S0090-8258(20)32330.
PubMed Abstract available

BRIEGER KK, Peterson S, Lee AW, Mukherjee B, et al
Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival.
Gynecol Oncol. 2020 Jul 5. pii: S0090-8258(20)32296.
PubMed Abstract available

DERQUIN F, Floquet A, Hardy-Bessard AC, Edeline J, et al
Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network.
Gynecol Oncol. 2020 Jul 2. pii: S0090-8258(20)32315.
PubMed Abstract available

BAE-JUMP V
Unraveling the mystery of clear cell endometrial cancer.
Gynecol Oncol. 2020;158:1-2.
PubMed

June 2020

JONES TL, Sandler CX, Spence RR, Hayes SC, et al
Physical activity and exercise in women with ovarian cancer: A systematic review.
Gynecol Oncol. 2020 Jun 29. pii: S0090-8258(20)32300.
PubMed Abstract available

LAGO V, Fotopoulou C, Chiantera V, Minig L, et al
Indications and practice of diverting ileostomy after colorectal resection and anastomosis in ovarian cancer cytoreduction.
Gynecol Oncol. 2020 Jun 19. pii: S0090-8258(20)31132.
PubMed Abstract available

SIMPSON AN, Sutradhar R, Ferguson SE, Robertson D, et al
Perioperative outcomes of women with and without class III obesity undergoing hysterectomy for endometrioid endometrial cancer: A population-based study.
Gynecol Oncol. 2020 Jun 19. pii: S0090-8258(20)32295.
PubMed Abstract available

MARIA S, Faron M, Maulard A, Pautier P, et al
Long term follow-up of a large series of stage-II/III atypical proliferative serous ovarian tumors.
Gynecol Oncol. 2020 Jun 19. pii: S0090-8258(20)32304.
PubMed Abstract available

DILLEY J, Burnell M, Gentry-Maharaj A, Ryan A, et al
Ovarian cancer symptoms, routes to diagnosis and survival - Population cohort study in the 'no screen' arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
Gynecol Oncol. 2020 Jun 16. pii: S0090-8258(20)31029.
PubMed Abstract available

NICA A, Covens A, Parra-Herran C, May T, et al
Does timing of intraperitoneal chemotherapy initiation following primary cytoreductive surgery with bowel resection impact outcomes in patients with advanced ovarian cancer?
Gynecol Oncol. 2020 Jun 16. pii: S0090-8258(20)32293.
PubMed Abstract available

PYRZAK A, Chen L, Kocherginsky M, Barber EL, et al
Radiation and hormonal therapy for primary treatment of stage I endometrial cancer and long-term survival.
Gynecol Oncol. 2020 Jun 16. pii: S0090-8258(20)31088.
PubMed Abstract available

MARCHETTI C, Minucci A, D'Indinosante M, Ergasti R, et al
Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach.
Gynecol Oncol. 2020 Jun 15. pii: S0090-8258(20)32294.
PubMed Abstract available

MOORE KN, Birrer MJ, Marsters J, Wang Y, et al
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.
Gynecol Oncol. 2020 Jun 11. pii: S0090-8258(20)31124.
PubMed Abstract available

NARASIMHULU DM, McGree ME, Weaver AL, Jatoi A, et al
Frailty is a determinant of suboptimal chemotherapy in women with advanced ovarian cancer.
Gynecol Oncol. 2020 Jun 6. pii: S0090-8258(20)31131.
PubMed Abstract available

BOGANI G, Lopez S, Mantiero M, Ducceschi M, et al
Immunotherapy for platinum-resistant ovarian cancer.
Gynecol Oncol. 2020 Jun 6. pii: S0090-8258(20)31924.
PubMed Abstract available

STRAUBHAR AM, Filippova OT, Cowan RA, Lakhman Y, et al
A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative.
Gynecol Oncol. 2020 Jun 6. pii: S0090-8258(20)31126.
PubMed Abstract available

HAMILTON E, O'Malley DM, O'Cearbhaill R, Cristea M, et al
Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study.
Gynecol Oncol. 2020 Jun 5. pii: S0090-8258(20)31123.
PubMed Abstract available

MORRISON A, Nasioudis D
Reproductive outcomes following fertility-sparing surgery for malignant ovarian germ cell tumors: A systematic review of the literature.
Gynecol Oncol. 2020 Jun 5. pii: S0090-8258(20)31121.
PubMed Abstract available

VENERIS JT, Mahajan P, Frazier AL
Contemporary management of ovarian germ cell tumors and remaining controversies.
Gynecol Oncol. 2020 Jun 4. pii: S0090-8258(20)31075.
PubMed Abstract available

ARMEL SR, Volenik A, Demsky R, Malcolmson J, et al
Setting a baseline: A 7-year review of referral rates and outcomes for serous ovarian cancer prior to implementation of oncologist mediated genetic testing.
Gynecol Oncol. 2020 Jun 3. pii: S0090-8258(20)31082.
PubMed Abstract available

BOLAND JL, Zhou Q, Iasonos AE, O'Cearbhaill RE, et al
Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy.
Gynecol Oncol. 2020 Jun 2. pii: S0090-8258(20)31073.
PubMed Abstract available

ROCHE KL, Chi DS
Practical guidelines for triage to neoadjuvant chemotherapy in advanced ovarian cancer: Big risk, big reward...or too much risk?
Gynecol Oncol. 2020;157:561-562.
PubMed

CHAMBERS LM, Pendlebury A, Rose PG, Yao M, et al
Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer.
Gynecol Oncol. 2020 Jun 1. pii: S0090-8258(20)31018.
PubMed Abstract available

CHEN H, Gotimer K, De Souza C, Tepper CG, et al
Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma.
Gynecol Oncol. 2020;157:783-792.
PubMed Abstract available

DUSKA LR, Petroni GR, Varhegyi N, Brown J, et al
A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
Gynecol Oncol. 2020;157:585-592.
PubMed Abstract available

May 2020

KNISELY A, Huang Y, Melamed A, Tergas AI, et al
Travel distance, hospital volume and their association with ovarian cancer short- and long-term outcomes.
Gynecol Oncol. 2020 May 23. pii: S0090-8258(20)31085.
PubMed Abstract available

GLEESON M, Kentwell M, Meiser B, Do J, et al
The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients.
Gynecol Oncol. 2020 May 22. pii: S0090-8258(20)31028.
PubMed Abstract available

SMAZYNSKI J, Hamilton PT, Thornton S, Milne K, et al
The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.
Gynecol Oncol. 2020 May 20. pii: S0090-8258(20)30989.
PubMed Abstract available

MATSUO K, Chang EJ, Matsuzaki S, Mandelbaum RS, et al
Minimally invasive surgery for early-stage ovarian cancer: Association between hospital surgical volume and short-term perioperative outcomes.
Gynecol Oncol. 2020 May 10. pii: S0090-8258(20)30304.
PubMed Abstract available

LUO S, Zhang Y, Yang Y, Zhu S, et al
Clonal tumor mutations in homologous recombination genes predict favorable clinical outcome in ovarian cancer treated with platinum-based chemotherapy.
Gynecol Oncol. 2020 May 8. pii: S0090-8258(20)30995.
PubMed Abstract available

BOUCHARD-FORTIER G, Cusimano MC, Fazelzad R, Sajewycz K, et al
Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2020 May 6. pii: S0090-8258(20)30259.
PubMed Abstract available

SIVAKUMARAN T, Mileshkin L, Grant P, Na L, et al
Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study.
Gynecol Oncol. 2020 May 4. pii: S0090-8258(20)31016.
PubMed Abstract available

DAI Y, Wang Z, Wang J
Survival of microsatellite-stable endometrioid endometrial cancer patients after minimally invasive surgery: An analysis of the Cancer Genome Atlas data.
Gynecol Oncol. 2020 May 4. pii: S0090-8258(20)30984.
PubMed Abstract available

SONG F, Li L, Zhang B, Zhao Y, et al
Tumor specific methylome in Chinese high-grade serous ovarian cancer characterized by gene expression profile and tumor genotype.
Gynecol Oncol. 2020 May 1. pii: S0090-8258(20)30988.
PubMed Abstract available

April 2020

STAPLES JN, Peres LC, Camacho F, Alberg AJ, et al
Cardiometabolic comorbidities and epithelial ovarian cancer risk among African-American women in the African-American Cancer Epidemiology Study (AACES).
Gynecol Oncol. 2020 Apr 30. pii: S0090-8258(20)31010.
PubMed Abstract available

MONK BJ, Coleman RL, Moore KN, Herzog TJ, et al
COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies.
Gynecol Oncol. 2020 Apr 29. pii: S0090-8258(20)31013.
PubMed

CHEN Y, Li G
Gynecological malignancies with asymptomatic SARS-CoV-2 infection during the convalescence of outbreak.
Gynecol Oncol. 2020 Apr 29. pii: S0090-8258(20)31019.
PubMed

NASIOUDIS D, Ko EM, Haggerty AF, Cory L, et al
Performance of lymphadenectomy for apparent early stage malignant ovarian germ cell tumors in the era of platinum-based chemotherapy.
Gynecol Oncol. 2020 Apr 28. pii: S0090-8258(20)30306.
PubMed Abstract available

SEARLE G, Pounds R, Phillips A, Kehoe S, et al
Prolonged interruption of chemotherapy in patients undergoing delayed debulking surgery for advanced high grade serous ovarian cancer is associated with a worse prognosis.
Gynecol Oncol. 2020 Apr 25. pii: S0090-8258(20)30307.
PubMed Abstract available

MAJIDI A, Na R, Dixon-Suen S, Jordan SJ, et al
Common medications and survival in women with ovarian cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2020 Apr 18. pii: S0090-8258(20)30253.
PubMed Abstract available

HOOGSTAD-VAN EVERT JS, Bekkers R, Ottevanger N, Jansen JH, et al
Harnessing natural killer cells for the treatment of ovarian cancer.
Gynecol Oncol. 2020 Apr 5. pii: S0090-8258(20)30236.
PubMed Abstract available

AREND RC, Beer HM, Cohen YC, Berlin S, et al
Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect.
Gynecol Oncol. 2020 Apr 5. pii: S0090-8258(20)30180.
PubMed Abstract available

NARASIMHULU DM, Kumar A, Weaver AL, Langstraat CL, et al
Less guessing, more evidence in identifying patients least fit for cytoreductive surgery in advanced ovarian cancer: A triage algorithm to individualize surgical management.
Gynecol Oncol. 2020 Apr 1. pii: S0090-8258(20)30249.
PubMed Abstract available

CHEVROT A, Pouget N, Bats AS, Huchon C, et al
Fertility and prognosis of borderline ovarian tumor after conservative management: Results of the multicentric OPTIBOT study by the GINECO & TMRG group.
Gynecol Oncol. 2020;157:29-35.
PubMed Abstract available

SCOTT SA, Llaurado Fernandez M, Kim H, Elit L, et al
Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes.
Gynecol Oncol. 2020;157:36-45.
PubMed Abstract available

MUELLER JJ, Pedra Nobre S, Braxton K, Alektiar KM, et al
Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma.
Gynecol Oncol. 2020 Apr 1. pii: S0090-8258(20)30250.
PubMed Abstract available

March 2020

BENNETSEN AKK, Baandrup L, Aalborg GL, Kjaer SK, et al
Non-epithelial ovarian cancer in Denmark - Incidence and survival over nearly 40years.
Gynecol Oncol. 2020 Mar 26. pii: S0090-8258(20)30246.
PubMed Abstract available

GONZALEZ R, Gockley AA, Melamed A, Sugrue R, et al
Multivariable analysis of association of beta-blocker use and survival in advanced ovarian cancer.
Gynecol Oncol. 2020 Mar 25. pii: S0090-8258(20)30228.
PubMed Abstract available

RUSH SK, Swisher EM, Garcia RL, Pennington KP, et al
Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
Gynecol Oncol. 2020 Mar 19. pii: S0090-8258(20)30101.
PubMed Abstract available

BETELLA I, Turbitt WJ, Szul T, Wu B, et al
Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer.
Gynecol Oncol. 2020 Mar 16. pii: S0090-8258(20)30226.
PubMed Abstract available

WOLFORD JE, Bai J, Moore KN, Kristeleit R, et al
Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
Gynecol Oncol. 2020 Mar 13. pii: S0090-8258(20)30176.
PubMed Abstract available

LIONTOS M, Sotiropoulou M, Kaparelou M, Tzannis K, et al
Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy.
Gynecol Oncol. 2020 Mar 12. pii: S0090-8258(20)30224.
PubMed Abstract available

ROZE JF, Veldhuis WB, Hoogendam JP, Verheijen RHM, et al
Prognostic value of radiological recurrence patterns in ovarian cancer.
Gynecol Oncol. 2020 Mar 11. pii: S0090-8258(20)30219.
PubMed Abstract available

VAN WALREE IC, Bretveld R, van Huis-Tanja LH, Louwers JA, et al
Reasons for guideline non-adherence in older and younger women with advanced stage ovarian cancer.
Gynecol Oncol. 2020 Mar 11. pii: S0090-8258(20)30221.
PubMed Abstract available

LEVY T, Migdan Z, Aleohin N, Ben-Shem, et al
Retroperitoneal lymph node recurrence of epithelial ovarian cancer: Prognostic factors and treatment outcome.
Gynecol Oncol. 2020 Mar 6. pii: S0090-8258(20)30158.
PubMed Abstract available

HAQUE R, Skates SJ, Armstrong MA, Lentz SE, et al
Feasibility, patient compliance and acceptability of ovarian cancer surveillance using two serum biomarkers and Risk of Ovarian Cancer Algorithm compared to standard ultrasound and CA 125 among women with BRCA mutations.
Gynecol Oncol. 2020 Mar 4. pii: S0090-8258(20)30164.
PubMed Abstract available

PIERSON WE, Peters PN, Chang MT, Chen LM, et al
An integrated molecular profile of endometrioid ovarian cancer.
Gynecol Oncol. 2020 Mar 2. pii: S0090-8258(20)30144.
PubMed Abstract available

GONTHIER C, Douhnai D, Koskas M
Lymph node metastasis probability in young patients eligible for conservative management of endometrial cancer.
Gynecol Oncol. 2020 Mar 2. pii: S0090-8258(20)30157.
PubMed Abstract available

REINHOLDT K, Kjaer SK, Guleria S, Frederiksen K, et al
Risk of endometrial cancer among women with benign ovarian tumors - A Danish nationwide cohort study.
Gynecol Oncol. 2020 Mar 2. pii: S0090-8258(20)30178.
PubMed Abstract available

MOORE KN, Zorn KK
Germline and Somatic Testing in Ovarian Cancer: Shifting Sands of Recommendations.
Gynecol Oncol. 2020;156:515-516.
PubMed

POWELL CB, Littell RD, Landen CN Jr, Pramanik S, et al
Cytological sampling of fallopian tubes using a hysteroscopic catheter: A multi-center study.
Gynecol Oncol. 2020;156:636-640.
PubMed Abstract available

LENCK C, Chopin N, Gouy S, Bonsang-Kitzis H, et al
The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study.
Gynecol Oncol. 2020 Mar 1. pii: S0090-8258(20)30145.
PubMed Abstract available

February 2020

CHANG CP, Chen Y, Blackburn B, Abdelaziz S, et al
Genitourinary disease risks among ovarian cancer survivors in a population-based cohort study.
Gynecol Oncol. 2020 Feb 28. pii: S0090-8258(20)30162.
PubMed Abstract available

PLETT H, Harter P, Ataseven B, Heitz F, et al
Fertility-sparing surgery and reproductive-outcomes in patients with borderline ovarian tumors.
Gynecol Oncol. 2020 Feb 27. pii: S0090-8258(20)30102.
PubMed Abstract available

GLASER GE, Kalogera E, Kumar A, Yi J, et al
Outcomes and patient perspectives following implementation of tiered opioid prescription guidelines in gynecologic surgery.
Gynecol Oncol. 2020 Feb 24. pii: S0090-8258(20)30161.
PubMed Abstract available

PRAISS AM, Huang Y, St Clair CM, Tergas AI, et al
A modern assessment of the surgical pathologic spread and nodal dissemination of endometrial cancer.
Gynecol Oncol. 2020 Feb 21. pii: S0090-8258(20)30150.
PubMed Abstract available

O'MALLEY DM, Matulonis UA, Birrer MJ, Castro CM, et al
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
Gynecol Oncol. 2020 Feb 18. pii: S0090-8258(20)30090.
PubMed Abstract available

UEHARA T, Yoshida H, Fukuhara M, Yoshida M, et al
Efficacy of ascitic fluid cell block for diagnosing primary ovarian, peritoneal, and tubal cancer in patients with peritoneal carcinomatosis with ascites.
Gynecol Oncol. 2020 Feb 13. pii: S0090-8258(20)30099.
PubMed Abstract available

FREY MK, Lee SS, Gerber D, Schwartz ZP, et al
Facilitated referral pathway for genetic testing at the time of ovarian cancer diagnosis: uptake of genetic counseling and testing and impact on patient-reported stress, anxiety and depression.
Gynecol Oncol. 2020 Feb 11. pii: S0090-8258(20)30007.
PubMed Abstract available

PETERSEN S, Wilson AJ, Hirst J, Roby KF, et al
CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes.
Gynecol Oncol. 2020 Feb 7. pii: S0090-8258(20)30091.
PubMed Abstract available

PIAO J, Lee EJ, Lee M
Association between pelvic inflammatory disease and risk of ovarian cancer: An updated meta-analysis.
Gynecol Oncol. 2020 Feb 6. pii: S0090-8258(20)30097.
PubMed Abstract available

COLEMAN RL, Handley KF, Burger R, Molin GZD, et al
Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
Gynecol Oncol. 2020 Feb 6. pii: S0090-8258(20)30095.
PubMed Abstract available

ROJAS C, Tian C, Powell MA, Chan JK, et al
Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival.
Gynecol Oncol. 2020 Feb 3. pii: S0090-8258(20)30057.
PubMed Abstract available

SOLSKY I, Chen J, Rebbeck TR
Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations.
Gynecol Oncol. 2020;156:363-376.
PubMed Abstract available

DOGAN NU, Dogan S, Erol M, Uzun BT, et al
Cisterna chyli: An important landmark in laparoscopic paraaortic lymphadenectomy.
Gynecol Oncol. 2020;156:511.
PubMed Abstract available

VENERIS JT, Matulonis UA, Liu JF, Konstantinopoulos PA, et al
Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations.
Gynecol Oncol. 2020;156:488-497.
PubMed Abstract available

January 2020

KORENAGA TR, Ward KK, Saenz C, McHale MT, et al
The elevated risk of ovarian clear cell carcinoma among Asian Pacific Islander women in the United States is not affected by birthplace.
Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(20)30086.
PubMed Abstract available

SIEMON J, Galli J, Slomovitz B, Schlumbrecht M, et al
Disparities in care among patients with low-grade serous ovarian carcinoma.
Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(19)31871.
PubMed Abstract available

NASIOUDIS D, Mastroyannis SA, Latif NA, Ko EM, et al
Trends in the surgical management of malignant ovarian germ-cell tumors.
Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(20)30087.
PubMed Abstract available

CABASAG CJ, Butler J, Arnold M, Rutherford M, et al
Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A population-based study.
Gynecol Oncol. 2020 Jan 28. pii: S0090-8258(19)31877.
PubMed Abstract available

XUE C, Xu Y, Ye W, Xie Q, et al
Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor.
Gynecol Oncol. 2020 Jan 24. pii: S0090-8258(19)31804.
PubMed Abstract available

STEWART LM, Stewart CJR, Spilsbury K, Cohen PA, et al
Association between pelvic inflammatory disease, infertility, ectopic pregnancy and the development of ovarian serous borderline tumor, mucinous borderline tumor and low-grade serous carcinoma.
Gynecol Oncol. 2020 Jan 23. pii: S0090-8258(20)30080.
PubMed Abstract available

HAVRILESKY LJ, Lim S, Ehrisman JA, Lorenzo A, et al
Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment.
Gynecol Oncol. 2020 Jan 22. pii: S0090-8258(20)30070.
PubMed Abstract available

BOGANI G, Ditto A, Lopez S, Bertolina F, et al
Adjuvant chemotherapy vs. observation in stage I clear cell ovarian carcinoma: A systematic review and meta-analysis.
Gynecol Oncol. 2020 Jan 21. pii: S0090-8258(19)31875.
PubMed Abstract available

SLOMOVITZ B, Gourley C, Carey MS, Malpica A, et al
Low-grade serous ovarian cancer: State of the science.
Gynecol Oncol. 2020 Jan 20. pii: S0090-8258(19)31862.
PubMed Abstract available

FEKETE JT, Osz A, Pete I, Nagy GR, et al
Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients.
Gynecol Oncol. 2020 Jan 20. pii: S0090-8258(20)30006.
PubMed Abstract available

CADOO KA, Grisham RN, O'Cearbhaill RE, Boucicaut NN, et al
A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer.
Gynecol Oncol. 2020 Jan 17. pii: S0090-8258(20)30060.
PubMed Abstract available

NASIOUDIS D, Frey MK, Chapman-Davis E, Caputo TA, et al
Primary malignant ovarian carcinoid; management and outcomes.
Gynecol Oncol. 2020 Jan 17. pii: S0090-8258(20)30002.
PubMed Abstract available

ACOSTA-TORRES S, Fader AN
Laparoscopic splenectomy for secondary cytoreduction of ovarian cancer in a woman with localized splenic recurrence.
Gynecol Oncol. 2020 Jan 16. pii: S0090-8258(19)31842.
PubMed Abstract available

MERIDETH MA, Harney LA, Vyas N, Bachi A, et al
Gynecologic and reproductive health in patients with pathogenic germline variants in DICER1.
Gynecol Oncol. 2020 Jan 15. pii: S0090-8258(19)31867.
PubMed Abstract available

GHIRARDI V, Moruzzi MC, Bizzarri N, Vargiu V, et al
Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
Gynecol Oncol. 2020 Jan 14. pii: S0090-8258(20)30017.
PubMed Abstract available

LLAURADO FERNANDEZ M, Dawson A, Kim H, Lam N, et al
Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
Gynecol Oncol. 2020 Jan 14. pii: S0090-8258(19)31680.
PubMed Abstract available

BEAVIS AL, Yen TT, Stone RL, Wethington SL, et al
Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy?
Gynecol Oncol. 2020 Jan 13. pii: S0090-8258(19)31849.
PubMed Abstract available

BIXEL K, Vetter M, Davidson B, Berchuck A, et al
Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.
Gynecol Oncol. 2020 Jan 11. pii: S0090-8258(19)31837.
PubMed Abstract available

MORGAN RD, Banerjee S, Hall M, Clamp AR, et al
Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.
Gynecol Oncol. 2020 Jan 10. pii: S0090-8258(20)30005.
PubMed Abstract available

STALEY SA, Tucker K, Newton M, Ertel M, et al
Sarcopenia as a predictor of survival and chemotoxicity in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy.
Gynecol Oncol. 2020 Jan 10. pii: S0090-8258(20)30003.
PubMed Abstract available

RAFFONE A, Travaglino A, Mascolo M, Carotenuto C, et al
Histopathological characterization of ProMisE molecular groups of endometrial cancer.
Gynecol Oncol. 2020 Jan 10. pii: S0090-8258(20)30008.
PubMed Abstract available

WANG D, Zhu S, Jia C, Cao D, et al
Diagnosis and management of growing teratoma syndrome after ovarian immature teratoma: A single center experience.
Gynecol Oncol. 2020 Jan 9. pii: S0090-8258(19)31872.
PubMed Abstract available

MONK BJ, Herzog TJ, Wang G, Triantos S, et al
A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
Gynecol Oncol. 2020 Jan 8. pii: S0090-8258(19)31873.
PubMed Abstract available

FRAUNE C, Rosebrock J, Simon R, Hube-Magg C, et al
High homogeneity of MMR deficiency in ovarian cancer.
Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31861.
PubMed Abstract available

SIAMAKPOUR-REIHANI S, Cobb LP, Jiang C, Zhang D, et al
Differential expression of immune related genes in high-grade ovarian serous carcinoma.
Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31840.
PubMed Abstract available

PEIRETTI M, Candotti G, Fais ML, Ricciardi E, et al
Comparison between laparoscopy and laparotomy in the surgical re-staging of granulosa cell tumors of the ovary.
Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31870.
PubMed Abstract available

BREWER M, Angioli R, Scambia G, Lorusso D, et al
Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study.
Gynecol Oncol. 2020 Jan 6. pii: S0090-8258(19)31845.
PubMed Abstract available

GORRINGE KL, Cheasley D, Wakefield MJ, Ryland GL, et al
Therapeutic options for mucinous ovarian carcinoma.
Gynecol Oncol. 2020 Jan 2. pii: S0090-8258(19)31836.
PubMed Abstract available

VARGHESE A, Shih IM
Not All Peritoneal Implants Are Created Equal.
Gynecol Oncol. 2020;156:1-2.
PubMed

CHODAVADIA PA, Jacobs CD, Wang F, Havrilesky LJ, et al
Off-study utilization of experimental therapies: Analysis of GOG249-eligible cohorts using real world data.
Gynecol Oncol. 2020;156:154-161.
PubMed Abstract available

MHAWECH-FAUCEGLIA P, Izevbaye I, Spindler T, Wang G, et al
Genomic heterogeneity in peritoneal implants: A differential analysis of gene expression using nanostring Human Cancer Reference panel identifies a malignant signature.
Gynecol Oncol. 2020;156:6-12.
PubMed Abstract available

December 2019

SALMINEN L, Nadeem N, Jain S, Grenman S, et al
A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer.
Gynecol Oncol. 2019 Dec 27. pii: S0090-8258(19)31846.
PubMed Abstract available

JORGE S, McFaddin AS, Doll KM, Pennington KP, et al
Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.
Gynecol Oncol. 2019 Dec 27. pii: S0090-8258(19)31802.
PubMed Abstract available

WAMBECKE A, Ahmad M, Lambert B, Joly F, et al
The influence of long non-coding RNAs on the response to chemotherapy in ovarian cancer.
Gynecol Oncol. 2019 Dec 26. pii: S0090-8258(19)31841.
PubMed Abstract available

KAY AH, Venn M, Urban R, Gray HJ, et al
Postoperative narcotic use in patients with ovarian cancer on an Enhanced Recovery After Surgery (ERAS) pathway.
Gynecol Oncol. 2019 Dec 24. pii: S0090-8258(19)31839.
PubMed Abstract available

JONES NL, Xiu J, Rocconi RP, Herzog TJ, et al
Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer.
Gynecol Oncol. 2019 Dec 24. pii: S0090-8258(19)31694.
PubMed Abstract available

CONNOR YD, Miao D, Lin DI, Hayne C, et al
Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts.
Gynecol Oncol. 2019 Dec 21. pii: S0090-8258(19)31618.
PubMed Abstract available

AREND RC, Davis AM, Chimiczewski P, O'Malley DM, et al
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low g
Gynecol Oncol. 2019 Dec 20. pii: S0090-8258(19)31786.
PubMed Abstract available

MATSUO K, Machida H, Matsuzaki S, Grubbs BH, et al
Evolving population-based statistics for rare epithelial ovarian cancers.
Gynecol Oncol. 2019 Dec 18. pii: S0090-8258(19)31781.
PubMed Abstract available

NAUMANN RW, Coleman RL, Brown J, Moore KN, et al
Corrigendum to "Phase III trials in ovarian cancer: The evolving landscape of front line therapy" [Gynecol. Oncol. 153 (2019) 436-444].
Gynecol Oncol. 2019 Dec 16. pii: S0090-8258(19)31799.
PubMed

KRILL L, Deng W, Eskander R, Mutch D, et al
Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Gynecol Oncol. 2019 Dec 13. pii: S0090-8258(19)31795.
PubMed Abstract available

NASIOUDIS D, Latif NA, Simpkins F, Cory L, et al
Adjuvant chemotherapy for early stage endometrioid ovarian carcinoma: An analysis of the National Cancer Data Base.
Gynecol Oncol. 2019 Dec 13. pii: S0090-8258(19)31784.
PubMed Abstract available

ZHANG H, Wu X, Xu Z, Sun Z, et al
Impact of perioperative red blood cell transfusion on postoperative recovery and long-term outcome in patients undergoing surgery for ovarian cancer: A propensity score-matched analysis.
Gynecol Oncol. 2019 Dec 12. pii: S0090-8258(19)31798.
PubMed Abstract available

PERES LC, Sinha S, Townsend MK, Fridley BL, et al
Predictors of survival trajectories among women with epithelial ovarian cancer.
Gynecol Oncol. 2019 Dec 12. pii: S0090-8258(19)31803.
PubMed Abstract available

ZHANG W, Tan C, Xu M, Wu X, et al
Primary appendiceal mucinous neoplasm: Gynecological manifestations, management, and prognosis.
Gynecol Oncol. 2019 Dec 12. pii: S0090-8258(19)31681.
PubMed Abstract available

KRIMMEL-MORRISON JD, Ghezelayagh TS, Lian S, Zhang Y, et al
Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma.
Gynecol Oncol. 2019 Dec 12. pii: S0090-8258(19)31783.
PubMed Abstract available

RONCOLATO FT, O'Connell RL, Joly F, Lanceley A, et al
Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(>/=3) chemotherapy - The GCIG symptom
Gynecol Oncol. 2019 Dec 10. pii: S0090-8258(19)31558.
PubMed Abstract available

VERGOTE I, Bergfeldt K, Franquet A, Lisyanskaya AS, et al
A randomized phase III trial in patients with recurrent platinum sensitive ovarian cancer comparing efficacy and safety of paclitaxel micellar and Cremophor EL-paclitaxel.
Gynecol Oncol. 2019 Dec 9. pii: S0090-8258(19)31685.
PubMed Abstract available

GITTO SB, Kim H, Rafail S, Omran DK, et al
An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer.
Gynecol Oncol. 2019 Dec 6. pii: S0090-8258(19)31568.
PubMed Abstract available

FORSSE D, Tangen IL, Fasmer KE, Halle MK, et al
Blood steroid levels predict survival in endometrial cancer and reflect tumor estrogen signaling.
Gynecol Oncol. 2019 Dec 5. pii: S0090-8258(19)31782.
PubMed Abstract available

HINCHCLIFF E, Jazaeri AA
Sunset, or dawn of a new age for ovarian cancer vaccine therapy?
Gynecol Oncol. 2019;155:387-388.
PubMed

November 2019

VERGOTE I, Heitz F, Buderath P, Powell M, et al
A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.
Gynecol Oncol. 2019 Nov 29. pii: S0090-8258(19)31627.
PubMed Abstract available

TAKAYA H, Nakai H, Sakai K, Nishio K, et al
Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course.
Gynecol Oncol. 2019 Nov 27. pii: S0090-8258(19)31664.
PubMed Abstract available

NARASIMHULU DM, Bews KA, Hanson KT, Chang YH, et al
Using evidence to direct quality improvement efforts: Defining the highest impact complications after complex cytoreductive surgery for ovarian cancer.
Gynecol Oncol. 2019 Nov 27. pii: S0090-8258(19)31628.
PubMed Abstract available

MATSUO K, Machida H, Grubbs BH, Matsuzaki S, et al
Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study.
Gynecol Oncol. 2019 Nov 27. pii: S0090-8258(19)31482.
PubMed Abstract available

KIM J, Cho YJ, Ryu JY, Hwang I, et al
CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer.
Gynecol Oncol. 2019 Nov 24. pii: S0090-8258(19)31625.
PubMed Abstract available

COLLINS A, Miles GJ, Wood J, MacFarlane M, et al
Patient-derived explants, xenografts and organoids: 3-dimensional patient-relevant pre-clinical models in endometrial cancer.
Gynecol Oncol. 2019 Nov 22. pii: S0090-8258(19)31671.
PubMed Abstract available

MAI PL, Huang HQ, Wenzel LB, Han PK, et al
Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study.
Gynecol Oncol. 2019 Nov 21. pii: S0090-8258(19)31613.
PubMed Abstract available

STASENKO M, Tunnage I, Ashley CW, Rubinstein MM, et al
Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.
Gynecol Oncol. 2019 Nov 19. pii: S0090-8258(19)31615.
PubMed Abstract available

LE PAGE C, Rahimi K, Rodrigues M, Heinzelmann-Schwarz V, et al
Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
Gynecol Oncol. 2019 Nov 18. pii: S0090-8258(19)31670.
PubMed Abstract available

RODRIGUEZ-FREIXINOS V, Farinas-Madrid L, Gil-Martin M, Barretina-Ginesta P, et al
Corrigendum to 'Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients' [Gynecologic Oncology 152 (2019) 270-277].
Gynecol Oncol. 2019 Nov 16. pii: S0090-8258(19)31604.
PubMed

TAYLOR SE, Chu T, Elvin JA, Edwards RP, et al
Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer.
Gynecol Oncol. 2019 Nov 15. pii: S0090-8258(19)31616.
PubMed Abstract available

NISHIKIMI K, Tate S, Matsuoka A, Shozu M, et al
Learning curve of high-complexity surgery for advanced ovarian cancer.
Gynecol Oncol. 2019 Nov 14. pii: S0090-8258(19)31621.
PubMed Abstract available

GAGNO S, Poletto E, Bartoletti M, Quartuccio L, et al
A TGF-beta associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer.
Gynecol Oncol. 2019 Nov 8. pii: S0090-8258(19)31603.
PubMed Abstract available

MOORE KN, Miller A, Bell-McGuinn KM, Schilder RJ, et al
A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.
Gynecol Oncol. 2019 Nov 7. pii: S0090-8258(19)31569.
PubMed Abstract available

ALIMUJIANG A, Khoja L, Wiensch A, Pike MC, et al
"I am not a statistic" ovarian cancer survivors' views of factors that influenced their long-term survival.
Gynecol Oncol. 2019 Nov 6. pii: S0090-8258(19)31564.
PubMed Abstract available

FEHNIGER JE, Berger AA, Juckett L, Elvin J, et al
Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility.
Gynecol Oncol. 2019 Nov 5. pii: S0090-8258(19)31561.
PubMed Abstract available

CECERE SC, Giannone G, Salutari V, Arenare L, et al
Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
Gynecol Oncol. 2019 Nov 4. pii: S0090-8258(19)31607.
PubMed Abstract available

BEIRNE JP, McArt DG, Roddy A, McDermott C, et al
Defining the molecular evolution of extrauterine high grade serous carcinoma.
Gynecol Oncol. 2019;155:305-317.
PubMed Abstract available

ONG PY, Poon SL, Tan KT, Putti TC, et al
Using next-generation sequencing (NGS) platform to diagnose pathogenic germline BRCA1/2 mutations from archival tumor specimens.
Gynecol Oncol. 2019;155:275-279.
PubMed Abstract available

October 2019

O'CEARBHAILL RE, Deng W, Chen LM, Lucci JA 3rd, et al
A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: A
Gynecol Oncol. 2019 Oct 22. pii: S0090-8258(19)31536.
PubMed Abstract available

ALLDREDGE J, Serna-Gallegos T, Gallegos N, VanLeer JP, et al
Evaluation of clear cell subtypes of ovarian and uterine malignancies with anti-PD-L1 and anti-PD1 immunohistochemical expression and their association with stage and survival.
Gynecol Oncol. 2019 Oct 22. pii: S0090-8258(19)31565.
PubMed

TATEBE K, Hasan Y, Son CH
Adjuvant vaginal brachytherapy and chemotherapy versus pelvic radiotherapy in early-stage endometrial cancer: Outcomes by risk factors.
Gynecol Oncol. 2019 Oct 11. pii: S0090-8258(19)31541.
PubMed Abstract available

MARCHETTI C, Rosati A, Scaletta G, Pietragalla A, et al
Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study.
Gynecol Oncol. 2019 Oct 9. pii: S0090-8258(19)31545.
PubMed Abstract available

BERG T, Nottrup TJ, Roed H
Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis.
Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31547.
PubMed Abstract available

LABIDI-GALY SI, de La Motte Rouge T, Derbel O, Wolfer A, et al
Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.
Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31528.
PubMed Abstract available

KURODA T, Ogiwara H, Sasaki M, Takahashi K, et al
Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31559.
PubMed Abstract available

September 2019

HOLLIS RL, Stanley B, Iida Y, Thomson J, et al
Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma.
Gynecol Oncol. 2019 Sep 5. pii: S0090-8258(19)31487.
PubMed Abstract available

MAKII C, Ikeda Y, Oda K, Uehara Y, et al
Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma.
Gynecol Oncol. 2019 Sep 4. pii: S0090-8258(19)31480.
PubMed Abstract available

August 2019

MATSUO K, Cripe JC, Kurnit KC, Kaneda M, et al
Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer.
Gynecol Oncol. 2019 Aug 16. pii: S0090-8258(19)31458.
PubMed Abstract available

KILTS TP, Glaser GE, Langstraat CL, Kumar A, et al
Comparing risk stratification criteria for predicting lymphatic dissemination in endometrial cancer.
Gynecol Oncol. 2019 Aug 10. pii: S0090-8258(19)31456.
PubMed Abstract available

SALYER C, Kobelka C, Barrie A, Weintraub MR, et al
Clinical characteristics and outcomes in elderly women with BRCA1 and BRCA2 mutations.
Gynecol Oncol. 2019;154:374-378.
PubMed Abstract available

July 2019

BARTELS HC, Rogers AC, McSharry V, McVey R, et al
A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy.
Gynecol Oncol. 2019 Jul 23. pii: S0090-8258(19)31397.
PubMed Abstract available

CYBULSKA P, Paula ADC, Tseng J, Leitao MM Jr, et al
Molecular profiling and molecular classification of endometrioid ovarian carcinomas.
Gynecol Oncol. 2019 Jul 21. pii: S0090-8258(19)31398.
PubMed Abstract available

HUBBARD AK, Poynter JN
Global incidence comparisons and trends in ovarian germ cell tumors by geographic region in girls, adolescents and young women: 1988-2012.
Gynecol Oncol. 2019 Jul 11. pii: S0090-8258(19)31348.
PubMed Abstract available

June 2019

XIANG M, English DP, Kidd EA
Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma.
Gynecol Oncol. 2019 Jun 27. pii: S0090-8258(19)31336.
PubMed Abstract available

HENGEVELD EM, Zusterzeel PLM, Lajer H, Hogdall CK, et al
The value of surgical staging in patients with apparent early stage epithelial ovarian carcinoma.
Gynecol Oncol. 2019 Jun 20. pii: S0090-8258(19)31317.
PubMed Abstract available

TANG M, O'Connell RL, Amant F, Beale P, et al
PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.
Gynecol Oncol. 2019 Jun 18. pii: S0090-8258(19)31322.
PubMed Abstract available

DOTTINO JA, He W, Sun CC, Zhao H, et al
Centers for Medicare and Medicaid Services' Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) scores and gynecologic oncology surgical outcomes.
Gynecol Oncol. 2019 Jun 14. pii: S0090-8258(19)31280.
PubMed Abstract available

LIU JF, Gordon M, Veneris J, Braiteh F, et al
Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers.
Gynecol Oncol. 2019 Jun 13. pii: S0090-8258(19)31265.
PubMed Abstract available

BERGAMINI A, Cormio G, Ferrandina G, Lorusso D, et al
Conservative surgery in stage I adult type granulosa cells tumors of the ovary: Results from the MITO-9 study.
Gynecol Oncol. 2019 Jun 10. pii: S0090-8258(19)31273.
PubMed Abstract available

FRAZER JL, Hook CE, Addley HC, Jackson CR, et al
Recurrent ovarian immature teratoma in a 12-year-old girl: Implications for management.
Gynecol Oncol. 2019 Jun 5. pii: S0090-8258(19)31277.
PubMed Abstract available

May 2019

NASIOUDIS D, Kahn R, Chapman-Davis E, Frey MK, et al
Impact of hospital surgical volume on complete gross resection (CGR) rates following primary debulking surgery for advanced stage epithelial ovarian carcinoma.
Gynecol Oncol. 2019 May 31. pii: S0090-8258(19)31260.
PubMed Abstract available

NASIOUDIS D, Haggerty AF, Giuntoli RL 2nd, Burger RA, et al
Adjuvant chemotherapy is not associated with a survival benefit for patients with early stage mucinous ovarian carcinoma.
Gynecol Oncol. 2019 May 30. pii: S0090-8258(19)31233.
PubMed Abstract available

COHEN PA, Powell A, Bohm S, Gilks CB, et al
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
Gynecol Oncol. 2019 May 19. pii: S0090-8258(19)31181.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: